Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01240824 · ClinicalTrials.gov registry record · Early Phase 1
Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer
A Early Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01240824 is a Early Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 3 participants.
The verdict
NCT01240824, a Early Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a new potential treatment for non invasive bladder cancer is safe and if it leads to side effects such as irregular heart rate, agitation, or burning with urination. Patients who have early stage bladder cancer and will be receiving BCG, a bladder cancer therapy as recommended by a doctor, will be asked to participate in a study where they are given the standard BCG followed by the experimental drug, aminophylline. Although we hope this medicine may one day prove to help bladder cancer patients, at the current time we do not know if it has any benefits at all. We have data in mice that suggest that aminophylline slows the growth of tumors when coupled with BCG.
Interventions
- DRUG aminophylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01240824
The ClinicalTrials.gov registry entry for NCT01240824 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aminophylline is the first listed.
NCT01240824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01240824 about?
NCT01240824 is a clinical study titled "Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer". The purpose of this study is to evaluate whether a new potential treatment for non invasive bladder cancer is safe and if it leads to side effects such as irregular heart rate, agitation, or burning with urination. Patients who have early stage bladder cancer and will be receiving BCG, a bladder can...
What is the current status of trial NCT01240824?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2010-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01240824?
The interventions under investigation include: aminophylline (DRUG).
Who is sponsoring clinical trial NCT01240824?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.